The abstract is read at the publisher; the summary is JClub's.
Rapid mpox vaccine response at 20 cases reported with a one-dose strategy yields the greatest benefits versus costs, with net benefits up to US$220 million higher than responding at 100.
- Why it matters: Gavi needed evidence to decide how large an mpox vaccine stockpile should be to contain outbreaks and prevent widespread transmission in Gavi-eligible countries.
- What they did: A deterministic compartmental transmission model with vaccination was run for four subpopulations, then fed into a Monte Carlo cost-benefit analysis comparing one-dose and two-dose strategies with rapid versus delayed intervention.
- The result: A 1 000 000-dose stockpile produced the highest benefits-to-costs ratio, and rapid one-dose response reduced DALYs averted costs by 18% to 53% versus one-dose at 100 cases.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.